Literature DB >> 18291145

The Ross procedure in infants and young children.

Alexander Kadner1, Olivier Raisky, Alexandra Degandt, Daniel Tamisier, Damien Bonnet, Daniel Sidi, Pascal R Vouhé.   

Abstract

BACKGROUND: This study reviews our experience with the Ross procedure in infants and young children.
METHODS: From September 1993 to September 2004, 52 children less than 15 years of age underwent a Ross procedure. The patients ranged in age from 4 days to 15 years old (median, 5 years). Fifteen patients (29%) were less than 2 years of age. The predominant indication for the Ross procedure was aortic stenosis. Sixteen patients underwent a Ross-Konno procedure for severe left ventricular outflow tract obstruction. Thirty-four patients had 48 previous interventions. Preoperatively, 6 patients showed severe left ventricular dysfunction, and 2 of the patients required ventilation and inotropic support. Concomitant procedures were performed in 8 patients. Three patients had a mitral valve replacement, 2 patients had a ventricular septal defect closure and an aortic arch reconstruction, 2 patients had aortic arch reconstructions, and 1 patient had resection of a coarctation and a ventricular septal defect closure.
RESULTS: Patients were followed up for a median of 43 months (range, 1 to 130). Overall survival was 85% +/- 5% at 1 and 82% +/- 5% at 2, 5, and 10 years. Hospital mortality was 5 of 52 patients (9.6%). All deaths occurred in neonates or infants less than 2 months of age, who needed urgent surgery. Three patients died late of noncardiac causes. At last follow-up, all patients were classified in New York Heart Association functional class I or II. No patient had endocarditis of the autograft or the right ventricular outflow tract replacement. During the follow-up, no event of thrombembolism was observed. No patient required the insertion of a permanent pacemaker. Overall freedom from reoperation is 57% +/- 15% at 10 years. One patient required the replacement of the autograft at 6 months postoperatively. The development of mild aortic insufficiency was observed in 24 patients, and moderate aortic insufficiency in 1 patient during follow-up. Freedom from reoperation for the right ventricular outflow tract replacement is 60% +/- 15% at 10 years.
CONCLUSIONS: The Ross procedure represents an attractive approach to aortic valve disease in young children. However, a high early mortality rate has to be considered when performing this procedure in neonates or infants who present in critical preoperative condition.

Entities:  

Mesh:

Year:  2008        PMID: 18291145     DOI: 10.1016/j.athoracsur.2007.07.047

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Exercise stress echocardiography after childhood Ross surgery: functional outcome in 26 patients from a single institution.

Authors:  Linda B Pauliks; J Brian Clark; Ashley Rogerson; Amy DiPietro; John L Myers; Stephen E Cyran
Journal:  Pediatr Cardiol       Date:  2012-02-21       Impact factor: 1.655

2.  GENE EXPRESSION AND COLLAGEN FIBER MICROMECHANICAL INTERACTIONS OF THE SEMILUNAR HEART VALVE INTERSTITIAL CELL.

Authors:  Christopher A Carruthers; Christina M Alfieri; Erinn M Joyce; Simon C Watkins; Katherine E Yutzey; Michael S Sacks
Journal:  Cell Mol Bioeng       Date:  2012-05-01       Impact factor: 2.321

3.  The Ross procedure in children: a systematic review.

Authors:  Morgan K Moroi; Emile A Bacha; David M Kalfa
Journal:  Ann Cardiothorac Surg       Date:  2021-07

4.  The importance of hybrid stage I palliation for neonates with critical aortic stenosis and reduced left ventricular function.

Authors:  Yusuke Misumi; Takaya Hoashi; Koji Kagisaki; Satoshi Yazaki; Masataka Kitano; Kenichi Kurosaki; Isao Shiraishi; Hajime Ichikawa
Journal:  Pediatr Cardiol       Date:  2014-12-06       Impact factor: 1.655

5.  Ross procedure in children: 17-year experience at a single institution.

Authors:  Sharman P Tan Tanny; Matthew S Yong; Yves d'Udekem; Remi Kowalski; Gavin Wheaton; Luigi D'Orsogna; John C Galati; Christian P Brizard; Igor E Konstantinov
Journal:  J Am Heart Assoc       Date:  2013-04-19       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.